Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methadone to CAM2038 transfer without methadone reduction
ACTRN12625000385448Phase 2Recruiting
- Sponsor
- Camurus
- Start
- Sep 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CAM2038 and methadone in opioid use disorder (OUD), sponsored by Camurus. Primary endpoint: Proportion of participants receiving the third CAM2038 dose on Day 8. Started Sep 2025; status: recruiting.
02
Drugs
CAM2038methadone
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on ACTRN12625000385448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000385448.